Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,064.01
(
-0.63%
)
US TECH 100
25,947.70
(
0.68%
)
Dow Jones
49,447.43
(
0.00%
)
Brent Oil
95.44
(
0.45%
)
Bitcoin
78,285.60
(
2.56%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biopharm

Send PM Follow Ignore
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

biopharm

Re: BioBS2012 post# 202377

Monday, 01/12/2015 4:13:04 PM

Monday, January 12, 2015 4:13:04 PM

Post# of 347009
BioBS2012,

that Opdivo trial was not double blinded.. right? N= 272 also... correct?

Now, that means they stopped it early and didn't even meet n=272 so it would be interesting to see how far off from that # they were and how that # compares to a double blind study such as "Sunrise".

Lots of questions I have but seems like I have to wait till ASCO

The thinking out of the box would be if the FDA ever approved Bavituximab for all FDA approved SOC, then BMS is ready to go with Opdivo+Bavituximab and they don't have far to go to beat SOC

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote